© 2020 Jnana Therapeutics - All rights reserved.
Jnana to receive $40 million upfront and is eligible to receive milestone payments with potential for future payments exceeding $1 billion Boston, MA – July 21, 2020 – Jnana Therapeutics today announced a strategic, multi-target collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery of small molecule drugs directed at […]
Boston, Mass., October 1, 2019 – Jnana Therapeutics, a biotechnology company targeting the solute carrier (SLC) family of metabolite transporters to treat underserved diseases, today announced the appointment of Caroline Stark Beer as its chief business officer. Ms. Stark Beer joins Jnana after over a decade at Alnylam Pharmaceuticals, where she served in a variety of […]
Boston, Mass., April 5, 2019 – Jnana Therapeutics today announced the appointment of Donald Nicholson, Ph.D., an accomplished scientist and executive, as chair of its Board of Directors. Don most recently served as chief executive officer of Nimbus Therapeutics. “I am thrilled to welcome Don as chair of our Board of Directors. Don’s experience and […]
Stuart Schreiber, Ph.D. and Brian Cali, Ph.D. appointed to Board Inaugural SAB comprises renowned leaders in the investigation of disease biology and applications to drug discovery and development Boston, Mass. – Dec. 20, 2018 – Jnana Therapeutics today announced the appointment of two new members to its Board of Directors: Stuart Schreiber, Ph.D., a co-founder […]
Boston Mass. – Nov. 6, 2018 – Jnana Therapeutics today announced that Joanne Kotz, Ph.D., a company co-founder, has been named Chief Executive Officer. Dr. Kotz has served as Jnana’s president since December 2017. “Joanne has demonstrated exceptional leadership in guiding the company through its early stages of growth, and we believe she is the […]
Partnership Leverages Neurocrine’s Expertise in Neuroscience and Jnana’s Proprietary Drug Discovery Platform Targeting the Solute Carrier Family of Transporters SAN DIEGO and BOSTON, Oct. 9, 2018 – Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Jnana Therapeutics Inc. today announced that they have entered into a research collaboration aimed at discovering novel small molecule therapeutics for multiple […]
Boston, Mass. – October 2, 2018 – Jnana Therapeutics today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Jnana Therapeutics was launched in 2017 to build the first drug discovery platform targeting the […]
Top-tier syndicate backs serial entrepreneur and world-renowned academics Stuart Schreiber and Ramnik Xavier Boston, Mass., December 14, 2017 – Jnana Therapeutics Inc. today announced a $50 million Series A financing. The company is building the first drug discovery platform dedicated to targeting the solute carrier (SLC) family of transporters, the cell’s metabolic gates. Jnana’s proprietary […]
Chemical and Engineering News, October 2018
Scripps Research, April 2020
2020 Fall ACS Meeting - Joel Barrish (CSO)
By Joanne Kotz (CEO) and Joel Barrish (CSO)
This links to an external website. Merus is not responsible for any third party content.